Pfizer vaccine: How I’m investing now

Pfizer’s coronavirus vaccine has been described as a ‘game-changer’ for stocks. Here, Motley Fool writer Edward Sheldon looks at where he is investing now.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

News that pharmaceutical giant Pfizer has developed a coronavirus vaccine sent UK shares higher this week. This vaccine has been described as a ‘game-changer’ for stocks. As a result, investors have been scrambling to reposition their portfolios. 

Here, I’m going to look at where I’m investing my own money now that a coronavirus vaccine is on the horizon. These are the stocks I’m buying.

Pfizer vaccine: a game-changer? 

On the back of the vaccine news, many investors are now piling into the sectors that were hit the hardest by Covid-19, such as airlines, oil, and hospitality. However, this is not an approach I’m going to take. A vaccine will certainly benefit companies in these industries. Yet many may continue to face challenges for a while.

Airlines, for example, may not return to normal for years, despite a vaccine. The coronavirus has devastated this industry, and demand may be depressed for years. Aviation analyst John Strickland summed up the situation well. He responded to the vaccine development by saying: “This news is certainly very welcome but it would be massively premature to say that the airline sector can now return to normal. Enormous damage has already been done and we can expect failures this winter”.

Where I’m investing now

So, where will I be investing now that a vaccine is on the cards? Well, in recent years, I’ve been focusing my portfolio on three main types of stocks. I plan to continue investing this way going forward.

Large-cap technology stocks are one area of the stock market I’ve been focusing on. Companies I’ve invested in include Microsoft, Amazon, and Mastercard. In my view, all of these companies are well placed to benefit from the digital revolution. Amazon, for example, is benefiting from the growth of online shopping. Mastercard is benefiting from the shift to digital payments. Microsoft is benefiting from the growth of the cloud. I think these kinds of stocks should do well in the years ahead irrespective of what happens with Covid-19.

Large-cap dividend stocks are another area of the market I’ve focused on. Some examples of companies I’ve invested in include Diageo, Reckitt Benckiser, Unilever, and Smith & Nephew. All of these stocks have solid long-term growth potential. However, they’re a little less volatile than my growth stocks which means they bring stability to my portfolio. 

Finally, I’ve also invested a little bit of money in small-cap growth stocks. These kinds of stocks are higher risk. However, they have the potential for explosive gains. Some examples of stocks I’ve bought include dotDigitalKeywords Studios, and freelance employment platform operator Upwork.

My goal: strong long-term returns

All of the companies I am investing in are exposed to powerful growth themes such as increased digitalisation, the ageing population, and the rise of wealth in the emerging markets. This means they should grow significantly over time. All have competitive advantages which should protect market share.

Meanwhile, with the exception of a few of the smaller companies I own, most companies are highly profitable. This increases the chances that they will turn out to be good long-term investments.

I believe this focus on highly-profitable companies with strong growth prospects should deliver strong returns in the long run.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in Amazon, Microsoft, Mastercard, Reckitt Bencksiser, Unilever, Diageo, Smith & Nephew, Upwork, Keywords Studios and dotDigital. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool’s board of directors. The Motley Fool UK owns shares of and has recommended Amazon, Mastercard, and Microsoft. The Motley Fool UK has recommended Diageo, dotDigital Group, Keywords Studios, and Unilever and recommends the following options: long January 2021 $85 calls on Microsoft, short January 2021 $115 calls on Microsoft, short January 2022 $1940 calls on Amazon, and long January 2022 $1920 calls on Amazon. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Potentially 42% undervalued, is this FTSE 100 company a sleeping giant?

The FTSE 100 is full of opportunities for the patient investor, and I think I may have found one that…

Read more »

Investing Articles

AstraZeneca, a mega-cap growth stock that just got cheaper!

Our writer takes a closer look at this growth stock -- which also happens to be the largest company of…

Read more »

Investing Articles

How I’d invest £5,000 in FTSE growth stocks right now

Sumayya Mansoor explains why she’s bullish about these FTSE growth stocks, and would be willing to buy some shares.

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

ITV shares down after revenue guidance cut in first-half interim results

After releasing results this morning, the ITV share price slumped. But with several metrics looking positive, how will this effect…

Read more »

Investing Articles

This FTSE 100 stock’s down 50%, and a director just bought 8,000 shares

Directors of this blue-chip company have been snapping up a load of its shares. Should I do likewise and buy…

Read more »

Investing Articles

The BT share price is far too cheap, analysts say!

The BT share price fell on Thursday 25 July after the company's Q1 results. Dr James Fox takes a closer…

Read more »

Investing Articles

Is this the start of a stock market crash?

Global stock markets are experiencing some turbulence at the moment. Could investors be looking at a major decline in share…

Read more »

Investing Articles

As the Anglo American share price holds up on H1 results, should I buy?

Failed takeover attempts and major restructuring all affect the Anglo American share price. Here's what's happening at H1 time.

Read more »